WO2015155704A1 - Procédé amélioré de préparation du monohydrate du dichlorhydrate de pramipexole - Google Patents

Procédé amélioré de préparation du monohydrate du dichlorhydrate de pramipexole Download PDF

Info

Publication number
WO2015155704A1
WO2015155704A1 PCT/IB2015/052542 IB2015052542W WO2015155704A1 WO 2015155704 A1 WO2015155704 A1 WO 2015155704A1 IB 2015052542 W IB2015052542 W IB 2015052542W WO 2015155704 A1 WO2015155704 A1 WO 2015155704A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
salt
methanol
dihydrochloride monohydrate
Prior art date
Application number
PCT/IB2015/052542
Other languages
English (en)
Inventor
Pravin Patil
Prakash PANSARE
Ashutosh JAGTAP
Dhileepkumar Krishnamurthy
Original Assignee
Piramal Enterprises Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Limited filed Critical Piramal Enterprises Limited
Publication of WO2015155704A1 publication Critical patent/WO2015155704A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems

Definitions

  • the present invention relates to a process for the preparation of the dihydrochloride monohydrate salt of (S)-2-amino-4,5,6,7-tetrahydro-6- (propylamino)benzothiazole ("referred to herein as 'Pramipexole' or the compound of formula I").
  • the present invention provides an improved process for the preparation of the compound of formula I from (S)-2,6- diamino-4,5,6,7-tetrahydrobenzthiazole (referred to herein as the compound of formula II) and further conversion of the compound of formula I into its dihydrochloride monohydrate salt.
  • Pramipexole (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole, represented by the following formula I (the compound of formula I), is a dopamine D2/D3 agonist used for treatment of Schizophrenia, and particularly for the treatment of Parkinson's disease. Pramipexole is marketed in the form of dihydrochloride monohydrate salt under the brand name Mirapex.
  • the compound of formula I is disclosed in US Patent no. 4,886,812 (US '812 Patent).
  • US' 812 Patent also describes a process for the preparation of the compound of formula I and its dihydrochloride monohydrate salt involving the propylation reaction of the compound of formula II with n-propylbromide as a propylating agent in the presence of potassium carbonate by using methanol as a solvent to provide the reaction mixture.
  • the resulting reaction mixture is then refluxed for 3 hours. After completion of the reaction, water is added to the reaction mixture.
  • the reaction mixture is then extracted with ethyl acetate and concentrated to obtain the residue.
  • Indian Patent Application no. 694/MUM/2006 describes a process for the preparation of the dihydrochloride monohydrate salt of the compound of formula I involving treating the alcoholic solution of the compound of formula I with hydrochloric acid and precipitating the dihydrochloride monohydrate salt of the compound of formula I by addition of water.
  • the process disclosed in this patent application does not involve any purification step for the purification of the compound of formula I or its dihydrochloride monohydrate salt and thus, the final active pharmaceutical ingredient (API), the dihydrochloride monohydrate salt of the compound of formula I prepared by this process does not have the desired pharmaceutically acceptable purity.
  • Indian patent application no. 605/MUM/2008 describes a process for the preparation of the dihydrochloride salt of the compound of formula I.
  • the process for the preparation of the dihydrochloride salt of the compound of formula I involves the propylation reaction of the compound of formula II with n-propanal as a propylating agent by using a mixture of methanol and water as the solvent.
  • glacial acetic acid and sodium borohydride are charged and the reaction mixture is stirred for 30-40 minutes at a temperature of 15 to 20°C.
  • the reaction mixture is then cooled to -5 to 0°C and to the reaction mixture; second lot of n-propanal with methanol and sodium borohydride is added.
  • the resulting reaction mixture is stirred for 30-40 minutes and quenched with brine solution.
  • the reaction mixture is distilled under vacuum to obtain a residue.
  • the precipitated dihydrochloride salt of the compound of formula I is dissolved in a mixture of ethanol and water; and filtered through hyflo. The filtrate is then distilled under vacuum and recrystallised by using ethanol to obtain the pure dihydrochloride salt of the compound of formula I.
  • the process disclosed in said patent involves the use of 3 molar equivalents of sodium borohydride and n- propanal which renders the process costlier and hence, this process is not viable for scale up.
  • the processes for the preparation of the compound of formula I as disclosed in the afore discussed patent documents involve the alkylation reaction of the compound of formula II with the 3-4 molar equivalents of propylating agent in the presence of an organic solvent to obtain (S)-2-amino-6-propinamido- 4,5,6,7-tetrahydrobenzothiazole.
  • the obtained (S)-2-amino-6-propinamido- 4,5,6,7-tetrahydrobenzothiazole is reduced insitu by addition of 3-4 molar equivalents of sodium borohydride to obtain the compound of formula I,which is further converted into its dihydrochloride monohydrate salt.
  • the process for the preparation of the compound of formula I involves the reductive alkylation of the compound of formula II.
  • one major impurity viz (6S)-,2,6-benzothiazolediamine,4,5,6,7- tetrahydro-N ⁇ A ⁇ -dipropyl of formula III (hereinafter referred to as 'impurity B') is generated.
  • the purification of the compound of formula I by using acetonitrile does not provide the product, the dihydrochloride monohydrate salt of the compound of formula I having pharmaceutical acceptable purity.
  • the process described in said patent application requires 3 molar equivalents of n-propanal and sodium borohydride based on the compound of formula II. N-propanal and sodium borohydride are expensive reagents and therefore, use of the same in an excess amount renders the whole process costly.
  • An object of the present invention is to provide an improved process for the preparation of the dihydrochloride monohydrate salt of the compound of formula I comprising reacting the compound of formula II with n-propanal and sodium borohydride using a mixture of methanol and dichloromethane (DCM) as a solvent.
  • Another object of the present invention is to provide an improved process for the preparation of the dihydrochloride monohydrate salt of the compound of formula I using minimum molar equivalents of n-propanal and sodium borohydride.
  • Another object of the present invention is to provide an improved process for the preparation of the dihydrochloride monohydrate salt of the compound of formula I comprising the preparation of the compound of formula I by the reaction of the compound of formula II with n-propanal and sodium borohydride using a mixture of methanol and dichloromethane (DCM) as the solvent and conversion of the resulting compound of formula I to its monohydrochloride salt followed by recrystallisation of the monohydrochloride salt of the compound of formula I and finally, its conversion to the dihydrochloride monohydrate salt of the compound of formula I.
  • DCM dichloromethane
  • the process for the preparation of the compound of formula I comprising the reaction of the compound of formula II with n-propanal and sodium borohydride using the mixture of methanol and DCM as a solvent to obtain the compound of formula I requires less molar equivalents of sodium borohydride and n-propanal.
  • the further conversion of the compound of formula I to its monohydrochloride salt followed by recrystallisation of the resulting monohydrochloride salt of the compound of formula I and further conversion of the pure monohydrochloride salt to the dihydrochloride monohydrate salt of the compound of formula I results in removing the individual impurity A, B and C less than 0.15% which ultimately results the product, the dihydrochloride monohydrate salt of the compound of formula I with higher purity.
  • the present invention relates to an improved process for the preparation of the dihydrochloride monohydrate salt of the compound of formula I.
  • the improved process for the preparation of the dihydrochloride monohydrate salt of the compound of formula I involves reaction of the compound of formula II with n-propanal and sodium borohydride using the mixture of methanol and DCM as a solvent to obtain the compound of formula I and further conversion of the compound of formula I to its monohydrochloride salt followed by recrystallisation of the resulting monohydrochloride salt of the compound of formula I and further conversion of the pure monohydrochloride salt to the dihydrochloride monohydrate salt of the compound of formula I.
  • the compound of formula I is obtained by reacting the compound of formula II with propanal and sodium borohydride using a mixture of methanol and dichloromethane (DCM) as the solvent.
  • the compound of formula I as obtained in the step (A) is further converted into its monohydrochloride salt in the step (B).
  • step (C) the monohydrochloride salt as obtained in step (B) purified with the mixture of methanol-water and further converted into dihydrochloride monohydrate salt in the step (D).
  • n- propanal is used in an amount ranging from 1 to 2 molar equivalents based on the compound of formula II.
  • step (A) of the process sodium borohydride is used in an amount ranging from 0.4 to 1 molar equivalent based on the compound of formula II.
  • methanol is used in an amount ranging from 15 to 20 volumes based on the compound of formula II.
  • DCM is used in an amount ranging from 15 to 20 volumes based on the compound of formula II.
  • the ratio of methanol to DCM used is 1: 1.
  • the organic solvent used in the step (B) of the process is selected from the group consisting of methanol, isopropyl alcohol, toluene, methyl tert-butyl ether (MTBE), n-hexane and ethyl acetate or a mixture thereof.
  • the organic solvent or the mixture of organic solvents is used in an amount ranging from 1 to 10 volumes based on the compound of formula II.
  • methanol is used in an amount ranging from 2 to 15 volumes based on the compound of formula II.
  • step (C) of the process water is used in an amount ranging from 0.03 to 0.07% based on the compound of formula II.
  • step (D) of the process isopropyl alcohol is used in an amount ranging from 2 to 15 volumes based on the compound of formula II.
  • the starting material of the process i.e. the compound of formula II is a known compound and can be prepared by a person skilled in the art by following methods described in the art, for example, by the process described in WO2008104847.
  • the process involves reaction of N-(4-oxocyclohexyl) acetamide with thiourea in the presence of bromine and acetic acid to obtain a reaction mixture.
  • dilute sulphuric acid was added to obtain sulphate salt of the compound of formula II.
  • sodium hydroxide was added to obtain the racemic compound of formula II.
  • the racemic compound of formula II was further resolved using tartaric acid to obtain the S isomer of the compound of formula II.
  • the process for the preparation of the dihydrochloride monohydrate salt of the compound of formula I involves reaction of the compound of formula II with n-propanal and sodium borohydride using a mixture of methanol and dichloromethane (DCM) as the solvent at a temperature of 25-30°C. After completion of the reaction, the reaction mixture was quenched with brine solution. The quenched reaction mixture was further concentrated up to 15-16 volumes under vacuum at a temperature of 50-55°C. The reaction mixture was cooled to a temperature of 15-20°C. To the reaction mixture, potassium carbonate, ethyl acetate and methanol were charged. The two layers formed were separated. The organic layer was then concentrated up to 7 to 8 volumes.
  • DCM dichloromethane
  • the conversion of the compound of formula I into its monohydochoride salt involves the addition of 1 mole equivalent of concentrated hydrochloric acid to the solution of the compound of formula I in isopropyl alcohol (IPA) at a temperature of 15-20°C to obtain monohydrochloride salt of the compound of formula I.
  • IPA isopropyl alcohol
  • the obtained monohydrochloride salt of the compound of formula I was then filtered and washed with isopropyl alcohol.
  • the monohydrochloride salt of the compound of formula I was then purified using a mixture of methanol and water.
  • the purification of the monohydrochloride salt of the compound of the formula I involves the charging of the monohydrochloride salt of the compound of formula I and the mixture of methanol-water to the reaction flask and the reaction mixture was heated to the reflux temperature. The reaction mixture was then cooled to a temperature of 25-30°C to precipitate solid. The precipitated solid was then filtered and washed with isopropyl alcohol (IPA) to obtain the pure monohydrochloride salt of the compound of formula I which was further converted into the dihydrochloride monohydrate salt of the compound of formula I.
  • IPA isopropyl alcohol
  • the process for the conversion of the pure monohydrochloride salt of the compound of formula I into the corresponding dihydrochloride monohydrate salt involves the charging of the pure monohydrochloride salt of the compound of formula I and isopropyl alcohol to the reaction flask at 25-30°C. To the reaction mass 1 mole equivalent of concentrate dihydrochloric acid was added at a temperature of 10-15°C to precipitate solid. The precipitated solid was then filtered and dried under vacuum to obtain the dihydrochloride monohydrate salt of the compound of formula I.
  • the inventors of the present invention have observed that the dihydrochloride monohydrate salt of the compound of formula I prepared from the compound of formula II through an improved process involving the reductive amination of the compound of formula II with n-propanal and sodium borohydride using a mixture of methanol and dichloromethane (DCM) as a solvent to obtain the compound of formula I, conversion of the compound of formula I into its monohydrate salt followed by the recrystallization of the monohydrochloride salt of the compound of formula I with a mixture of methanol-water to obtain the pure monohydrochloride salt of the compound of formula I and conversion of the pure monohydrochloride salt of the compound of formula I into the dihydrochloride monohydrate salt of the compound of formula I having individual impurity A, B and C below 0.15% and having pharmaceutical acceptable purity.
  • DCM dichloromethane
  • reaction mixture was quenched with brine solution.
  • the quenched reaction mixture was further concentrated up to 15-16 volumes at 50-55°C under vacuum.
  • the reaction mixture was cooled to 15-20°C.
  • potassium carbonate (150 g) ethyl acetate (900 ml) and methanol (100 ml) were charged. The two layers formed were separated. The organic layer was then concentrated up to 7 to 8 volumes.
  • ethyl acetate (500 ml) and brine solution (240 g) were added. The two layers formed were separated. The organic layer was treated with activated charcoal and filtered through hyflo. The organic layer was then concentrated under vacuum to obtain residue.
  • SPL (Area) - is area of peak due to impurities in sample preparation.
  • STD (Area) - is mean area of peak of Pramipexole in reference solution (a) for injections.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé amélioré de préparation du sel monohydrate du dichlorhydrate de (S)-2-amino-4,5,6,7-tétrahydro-6-(propylamino)benzothiazole (le composé de formule I) consistant à faire réagir le composé de formule II avec du n-propanal et du borohydrure de sodium en faisant appel à un mélange de méthanol et de dichlorométhane (DCM) en tant que solvant afin d'obtenir le composé de formule I ; puis à convertir le composé de formule I en son sel monochlorhydrate ; à purifier ledit sel monochlorhydrate du composé de formule I ; et enfin à convertir ledit sel monochlorhydrate pur du composé de formule I en sel monohydrate de dichlorhydrate.
PCT/IB2015/052542 2014-04-09 2015-04-08 Procédé amélioré de préparation du monohydrate du dichlorhydrate de pramipexole WO2015155704A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1307/MUM/2014 2014-04-09
IN1307MU2014 2014-04-09

Publications (1)

Publication Number Publication Date
WO2015155704A1 true WO2015155704A1 (fr) 2015-10-15

Family

ID=54287376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/052542 WO2015155704A1 (fr) 2014-04-09 2015-04-08 Procédé amélioré de préparation du monohydrate du dichlorhydrate de pramipexole

Country Status (1)

Country Link
WO (1) WO2015155704A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107540632A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN107540634A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021214A2 (fr) * 2009-08-07 2011-02-24 Msn Laboratories Limited Procédé amélioré pour la préparation de (s)-2-amino-4,5,6,7-tétrahydro-6-(propylamino)benzothiazole et de ses sels pharmaceutiquement acceptables
CN103626718A (zh) * 2013-12-13 2014-03-12 山东新华制药股份有限公司 盐酸普拉克索的工业化制备方法
CN104072442A (zh) * 2013-03-28 2014-10-01 成都弘达药业有限公司 一种化合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021214A2 (fr) * 2009-08-07 2011-02-24 Msn Laboratories Limited Procédé amélioré pour la préparation de (s)-2-amino-4,5,6,7-tétrahydro-6-(propylamino)benzothiazole et de ses sels pharmaceutiquement acceptables
CN104072442A (zh) * 2013-03-28 2014-10-01 成都弘达药业有限公司 一种化合物及其制备方法
CN103626718A (zh) * 2013-12-13 2014-03-12 山东新华制药股份有限公司 盐酸普拉克索的工业化制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107540632A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法
CN107540634A (zh) * 2016-06-27 2018-01-05 江苏神龙药业股份有限公司 一种普拉克索单盐酸盐的新晶型及其制备方法

Similar Documents

Publication Publication Date Title
US9611225B2 (en) Process for preparation of androgen receptor antagonist
US8952173B2 (en) Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds
US20090105483A1 (en) Process for the preparation of pramipexole base and/or its salts
WO2008041240A1 (fr) Procédé de préparation de (s)-pramipexole et de ses intermédiaires
US20110263719A1 (en) Polymorphic form of rasagiline mesylate
WO2008104847A2 (fr) Procédés de préparation du pramipexole et de ses sels
WO2011021214A2 (fr) Procédé amélioré pour la préparation de (s)-2-amino-4,5,6,7-tétrahydro-6-(propylamino)benzothiazole et de ses sels pharmaceutiquement acceptables
US11001574B2 (en) Process to obtain a tetrahydroisoquinoline derivative
US20220162154A1 (en) D-metyrosine compositions and methods for preparing same
EP3782992A1 (fr) Nouveau procédé de préparation de ranolazine
JP2008511684A (ja) アナストロゾール中間体についての精製方法
WO2015155704A1 (fr) Procédé amélioré de préparation du monohydrate du dichlorhydrate de pramipexole
US10426770B2 (en) Process for the preparation of Lurasidone hydrochloride
US9000158B2 (en) Process for preparing levosimendan and intermediates for use in the process
JPWO2011001976A1 (ja) スレオ−３−（３，４−ジヒドロキシフェニル）−ｌ−セリンの製造法
US20140243529A1 (en) Process for the preparation of lurasidone hydrochloride
US9630909B2 (en) Process for the preparation of nepafenac
US10822308B2 (en) Processes for the preparation of eluxadoline
US8106188B2 (en) Process for preparing olanzapine form I
EP2852592A1 (fr) Procédé de préparation de chlorhydrate de valacyclovir
CA2937417A1 (fr) Procede ameliore pour la preparation de trazodone et son sel de chlorhydrate
CA2593407A1 (fr) Procedes ameliores pour la synthese de l'olanzapine
TWI453182B (zh) Ｒ－β－胺基苯丁酸衍生物的製備方法
US8759581B2 (en) Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane
US20220389040A1 (en) An industrial process for resolution of chlocyphos

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15776441

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15776441

Country of ref document: EP

Kind code of ref document: A1